Observational analysis highlights public communication evolution at the European Medicines Agency, suggesting new challenges and opportunities arise from changing landscapes.
As the European Medicines Agency (EMA) marks its 30th anniversary with a series of events at its offices in Amsterdam, one area in the spotlight is EMA’s communication with the public. The Agency has made significant strides in this area over the past three decades, and it faces new challenges today. There are also exciting opportunities brought about by changes to the pharmaceutical and technological landscape.
No takes yet. Share an insight, caveat, or question.
Nacho Mbaeliachi (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: